AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29267994 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated devices, clinical training, and support for systems change
Number of subjects: 6
Study 29267994 — intervention group
Group type: COMPARATOR
Intervention: Comparison sites (control)
Number of subjects: 6
Study 26746173 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 34
Study 26746173 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain-Counterstrain (SCS)
Number of subjects: 34
Study 26746173 — intervention group
Group type: COMPARATOR
Intervention: Sham SCS
Number of subjects: 34
Study 24708193 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET/CT
Number of subjects: 300
Study 24708193 — intervention group
Group type: COMPARATOR
Intervention: US/chest radiography
Number of subjects: 300
Study 24708193 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine PET/CT
Number of subjects: 300
Study 22735317 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture anchor
Number of subjects: 40
Study 22735317 — intervention group
Group type: EXPERIMENTAL
Intervention: Transosseous suture
Number of subjects: 40
Study 20426957 — intervention group
Group type: EXPERIMENTAL
Intervention: Guaifenesin compound pseudoephedrine hydrochloride oral solution
Number of subjects: 412
Study 20426957 — intervention group
Group type: COMPARATOR
Intervention: Ambroxol hydrochloride oral solution
Number of subjects: 412
Study 18036464 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright positioning by a parent
Number of subjects: 118
Study 18036464 — intervention group
Group type: COMPARATOR
Intervention: Lying flat on an exam table (Control)
Number of subjects: 118
Study 16035979 — intervention group
Group type: EXPERIMENTAL
Intervention: Event recorder monitoring
Number of subjects: 310
Study 16035979 — intervention group
Group type: COMPARATOR
Intervention: Holter monitoring
Number of subjects: 310
Study 11932881 — intervention group
Group type: COMPARATOR
Intervention: Double-blind studies
Number of subjects: 28
Study 11932881 — intervention group
Group type: COMPARATOR
Intervention: Studies with larger rates of withdrawal
Number of subjects: 28
Study 11932881 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials with power calculations
Number of subjects: 28
Study 11932881 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials specifying outcomes
Number of subjects: 28
Study 11932881 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials with sample size per arm
Number of subjects: 28
Study 10404707 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 202
Study 10404707 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 202
Study 10404707 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium combined with Carbamazepine
Number of subjects: 202
Study 10404707 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 202
Study 10404707 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 202
Study 10404707 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponders at baseline
Number of subjects: 202
Study 10404707 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponders during pharmacotherapy
Number of subjects: 202
Study 10404707 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately abnormal EEGs
Number of subjects: 202
Study 10404707 — intervention group
Group type: EXPERIMENTAL
Intervention: Small sharp spikes
Number of subjects: 202
Study 10404707 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsleep
Number of subjects: 202
Study 7551920 — intervention group
Group type: COMPARATOR
Intervention: CDDP (120 mg/m2 day 1) + etoposide (100 mg/m2 days 1‐3) every 3 weeks (PE‐‐arm A)
Number of subjects: 393
Study 7551920 — intervention group
Group type: COMPARATOR
Intervention: CDDP (120 mg/m2 every 4 weeks) + mitomycin (8 mg/m2 days 1, 29, 71) + vindesine (3 mg/m2 days 1, 8, 15, 22 every 2 weeks) (MVP‐‐arm B)
Number of subjects: 393
Study 7551920 — intervention group
Group type: COMPARATOR
Intervention: CDDP (120 mg/m2 day 1) + mitomycin (6 mg/m2 day 1) + ifosfamide (3 g/m2 day 2) every 3 weeks (MIC‐‐arm C)
Number of subjects: 393
Study 2403992 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis labeled relaxation exercise
Number of subjects: 63
Study 2403992 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation labeled relaxation exercise
Number of subjects: 63
Study 2403992 — intervention group
Group type: COMPARATOR
Intervention: Neutral tape (Control)
Number of subjects: 63
Study 31173455 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 50 mg
Number of subjects: 175
Study 31173455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 31173455 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 175
Study 28732826 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler (GFF MDI) 2.4/9.6 mug
Number of subjects: 0
Study 28732826 — intervention group
Group type: COMPARATOR
Intervention: Formoterol fumarate metered dose inhaler (FF MDI) 9.6 mug
Number of subjects: 0
Study 24870575 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk walking in cold (8°C)
Number of subjects: 16
Study 24870575 — intervention group
Group type: COMPARATOR
Intervention: Brisk walking in neutral (20°C)
Number of subjects: 16
Study 23391032 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel microabrasion alone
Number of subjects: 10
Study 23391032 — intervention group
Group type: COMPARATOR
Intervention: Combined approach (enamel microabrasion and in-office bleaching)
Number of subjects: 10
Study 21664003 — intervention group
Group type: EXPERIMENTAL
Intervention: HEPA oxygen mask
Number of subjects: 0
Study 21664003 — intervention group
Group type: COMPARATOR
Intervention: Hudson-type mask
Number of subjects: 0
Study 20078201 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular symphysis bone grafting followed by postoperative orthodontic treatment
Number of subjects: 75
Study 20078201 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 75
Study 17603326 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillotomy (TT) using radiofrequency technique
Number of subjects: 74
Study 17603326 — intervention group
Group type: COMPARATOR
Intervention: Tonsillectomy (TE) (blunt dissection)
Number of subjects: 74
Study 17603326 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TT and TE groups
Number of subjects: 74
Study 15838199 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention (six sessions with safer sex information, interactive learning activities, and discussion groups facilitated by HIV-seropositive peers)
Number of subjects: 811
Study 15838199 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention (one session providing safer sex information)
Number of subjects: 811
Study 12457002 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide Novolizer
Number of subjects: 315
Study 12457002 — intervention group
Group type: COMPARATOR
Intervention: Pulmicort Turbuhaler
Number of subjects: 315
Study 9819039 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa (NovoSeven) administered at home
Number of subjects: 5
Study 9819039 — intervention group
Group type: COMPARATOR
Intervention: In-hospital management of bleeding episodes
Number of subjects: 5
Study 7648636 — intervention group
Group type: EXPERIMENTAL
Intervention: China-mode Hepatitis A attenuated live vaccine
Number of subjects: 62698
Study 7648636 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 62698
Study 7648636 — intervention group
Group type: EXPERIMENTAL
Intervention: Persons who missed vaccination in case group
Number of subjects: 62698
Study 7648636 — intervention group
Group type: COMPARATOR
Intervention: Mistakenly vaccinated individuals in control group
Number of subjects: 62698
Study 7648636 — intervention group
Group type: COMPARATOR
Intervention: External control group
Number of subjects: 62698
Study 2516430 — intervention group
Group type: EXPERIMENTAL
Intervention: HuIFN-beta (1 or 3 million international units per day for 4 or 12 weeks)
Number of subjects: 24
Study 2516430 — intervention group
Group type: EXPERIMENTAL
Intervention: HuIFN-beta
Number of subjects: 24
Study 2516430 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 24
Study 339935 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 mg three times a day)
Number of subjects: 20
Study 339935 — intervention group
Group type: COMPARATOR
Intervention: Mianserin (10 mg three times a day)
Number of subjects: 20
Study 339935 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.5 g/kg)
Number of subjects: 20
Study 30661847 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga-CaRe program (13 sessions supervised by an instructor and encouragement to self-practice daily)
Number of subjects: 4000
Study 30661847 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard care (3 sessions of health education)
Number of subjects: 4000
Study 29217503 — intervention group
Group type: EXPERIMENTAL
Intervention: PHR-based intervention group
Number of subjects: 80
Study 29217503 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 25832425 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg, po)
Number of subjects: 24
Study 25832425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 23786856 — intervention group
Group type: EXPERIMENTAL
Intervention: Max electrogram-guided approach
Number of subjects: 80
Study 23786856 — intervention group
Group type: COMPARATOR
Intervention: Linear approach
Number of subjects: 80
Study 21696982 — intervention group
Group type: EXPERIMENTAL
Intervention: NV1FGF (riferminogene pecaplasmid) administered intramuscularly
Number of subjects: 525
Study 21696982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 525
Study 19476405 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal phototherapy (allergy reliever SN‐206) used three times a day for 14 days
Number of subjects: 101
Study 19476405 — intervention group
Group type: COMPARATOR
Intervention: Placebo device used three times a day for 14 days
Number of subjects: 101
Study 16843257 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannequin group (35 students)
Number of subjects: 67
Study 16843257 — intervention group
Group type: COMPARATOR
Intervention: Control group (32 students)
Number of subjects: 67
Study 12766717 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 195
Study 12766717 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 195
Study 11075942 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir/lamivudine/zidovudine
Number of subjects: 232
Study 11075942 — intervention group
Group type: COMPARATOR
Intervention: lamivudine/zidovudine
Number of subjects: 232
Study 9488894 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II 1 ng kg‐1 min‐1
Number of subjects: 8
Study 9488894 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II 2 ng kg‐1 min‐1
Number of subjects: 8
Study 9488894 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 8
Study 9488894 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (in vitro)
Number of subjects: 8
Study 9488894 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (3 x 10(‐7)M and 10(‐6)M)
Number of subjects: 8
Study 8453387 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication discharge planning program (experimental group)
Number of subjects: 54
Study 8453387 — intervention group
Group type: COMPARATOR
Intervention: Usual informal discharge planning (control group)
Number of subjects: 54
Study 3530897 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg nocte (once at night)
Number of subjects: 594
Study 3530897 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 594
Study 3530897 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 594
Study 29794099 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordination exercises with concurrent mental tasks
Number of subjects: 500
Study 29794099 — intervention group
Group type: COMPARATOR
Intervention: Multisport exercises with mental tasks
Number of subjects: 500
Study 29794099 — intervention group
Group type: COMPARATOR
Intervention: Multisport exercises without mental tasks
Number of subjects: 500
Study 26395402 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning goals
Number of subjects: 90
Study 24717684 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low carbohydrate, high fat, non calorie‐restricted diet (LCK)
Number of subjects: 34
Study 24717684 — intervention group
Group type: COMPARATOR
Intervention: Moderate carbohydrate, low fat, calorie‐restricted diet (MCCR)
Number of subjects: 34
Study 22180581 — intervention group
Group type: EXPERIMENTAL
Intervention: ASSIST programme (peer-led intervention)
Number of subjects: 10730
Study 22180581 — intervention group
Group type: COMPARATOR
Intervention: Usual smoking education (control)
Number of subjects: 10730
Study 20674149 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 U of BoNTA
Number of subjects: 77
Study 20674149 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 U of BoNTA
Number of subjects: 77
Study 20674149 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 U and 750 U of BoNTA
Number of subjects: 77
Study 19138010 — intervention group
Group type: EXPERIMENTAL
Intervention: Single illumination of 100 Jcm(‐2) after 5 hours of incubation with 20% 5‐ALA
Number of subjects: 51
Study 19138010 — intervention group
Group type: COMPARATOR
Intervention: Two light fractions (50 plus 50 Jcm(‐2)) after 16 hours of incubation with 20% 5‐ALA
Number of subjects: 51
Study 15821888 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART (Highly Active Antiretroviral Therapy) for six months
Number of subjects: 10
Study 12456128 — intervention group
Group type: EXPERIMENTAL
Intervention: Project 4-Health program
Number of subjects: 1853
Study 12456128 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1853
Study 9512856 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA) removal
Number of subjects: 60
Study 9512856 — intervention group
Group type: COMPARATOR
Intervention: Tracheal extubation
Number of subjects: 60
Study 7899367 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for small cell lung carcinoma
Number of subjects: 1280
Study 7899367 — intervention group
Group type: COMPARATOR
Intervention: Pretherapeutic factors (Karnofsky index, alkaline phosphatase level, white cell count, age, presence of brain metastasis, presence of liver metastasis, initial extension)
Number of subjects: 1280
Study 2795362 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey-dominant formula
Number of subjects: 19
Study 2795362 — intervention group
Group type: COMPARATOR
Intervention: Casein-dominant formula
Number of subjects: 19
Study 144378 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically administered amine fluorides
Number of subjects: 0
Study 144378 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29508695 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB-FA (3 g/d)
Number of subjects: 11
Study 29508695 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 11
Study 29508695 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 11
Study 27440716 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-varying spectral analysis of EDA (TVSymp)
Number of subjects: 12
Study 27440716 — intervention group
Group type: COMPARATOR
Intervention: Time-domain and time-invariant spectral indices
Number of subjects: 12
Study 25052410 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxylamine-vitamin B6 combination (Diclectin)
Number of subjects: 257
Study 25052410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 23033348 — intervention group
Group type: EXPERIMENTAL
Intervention: Prethrombolytic antihypertensive treatment (AHT)
Number of subjects: 534
Study 23033348 — intervention group
Group type: COMPARATOR
Intervention: No prethrombolytic antihypertensive treatment (AHT)
Number of subjects: 534
Study 20099956 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 100
Study 20099956 — intervention group
Group type: EXPERIMENTAL
Intervention: CM + RP
Number of subjects: 100
Study 20099956 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 100
Study 18932056 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive prevention programme including hazard assessments, changes to housekeeping procedures, introduction of preventive products, awareness campaigns, and flooring changes.
Number of subjects: 0
Study 15965279 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular iron (200 mg daily)
Number of subjects: 15
Study 15965279 — intervention group
Group type: COMPARATOR
Intervention: Transfusion
Number of subjects: 15
Study 11847511 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrolides
Number of subjects: 365
Study 11847511 — intervention group
Group type: COMPARATOR
Intervention: Cephalosporins
Number of subjects: 365
Study 10231333 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg salbutamol
Number of subjects: 22
Study 10231333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 8676931 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug group (rifabutin 600 mg daily, ethambutol, clarithromycin 1000 mg twice daily)
Number of subjects: 229
Study 8676931 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug group
Number of subjects: 229
Study 8676931 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug group (rifabutin 600 mg)
Number of subjects: 229
Study 8676931 — intervention group
Group type: COMPARATOR
Intervention: Four-drug group (rifampin, ethambutol, clofazimine, ciprofloxacin)
Number of subjects: 229
Study 8676931 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug group (rifabutin 300 mg)
Number of subjects: 229
Study 1857652 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical music
Number of subjects: 121
Study 1857652 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine sounds
Number of subjects: 121
Study 1857652 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacifier
Number of subjects: 121
Study 1857652 — intervention group
Group type: EXPERIMENTAL
Intervention: Music and pacifier
Number of subjects: 121
Study 1857652 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine sounds and pacifier
Number of subjects: 121
Study 1857652 — intervention group
Group type: COMPARATOR
Intervention: Control (no nurses present and no pain reduction interventions)
Number of subjects: 121
Study 6287835 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA)
Number of subjects: 64
Study 6287835 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium gluconate (CG)
Number of subjects: 64
Study 6287835 — intervention group
Group type: COMPARATOR
Intervention: No mineral supplements (Control)
Number of subjects: 64
Study 30194457 — intervention group
Group type: EXPERIMENTAL
Intervention: Thulium laser enucleation of the prostate (ThuLEP)
Number of subjects: 115
Study 30194457 — intervention group
Group type: COMPARATOR
Intervention: Thulium laser resection of the prostate (TmLRP)
Number of subjects: 115
Study 30194457 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (ThuLEP and TmLRP)
Number of subjects: 115
Study 28201821 — intervention group
Group type: EXPERIMENTAL
Intervention: Cane group (using a cane daily whenever walking for 12 weeks)
Number of subjects: 0
Study 28201821 — intervention group
Group type: COMPARATOR
Intervention: Control group (not using any gait aid for 12 weeks)
Number of subjects: 0
Study 28201821 — intervention group
Group type: EXPERIMENTAL
Intervention: Cane group
Number of subjects: 0
Study 26273472 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 0
Study 26273472 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual internet-based Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 0
Study 26273472 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 26273472 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based MBCT
Number of subjects: 0
Study 26273472 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual internet-based MBCT
Number of subjects: 0
Study 26273472 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 0
Study 24639421 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Beginnings (HB) intervention
Number of subjects: 0
Study 22237690 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin (Alo)
Number of subjects: 71
Study 22237690 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin/Pioglitazone (Alo/Pio)
Number of subjects: 71
Study 22237690 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pbo)
Number of subjects: 71
Study 20846363 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human follicle-stimulating hormone
Number of subjects: 4040
Study 20846363 — intervention group
Group type: COMPARATOR
Intervention: Human menopausal gonadotrophins
Number of subjects: 4040
Study 17662390 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxemic reperfusion with aqueous oxygen (AO) for 90 min after PCI
Number of subjects: 269
Study 17662390 — intervention group
Group type: COMPARATOR
Intervention: Normoxemic blood autoreperfusion (control group)
Number of subjects: 269
Study 17662390 — intervention group
Group type: COMPARATOR
Intervention: Both groups (AO and control)
Number of subjects: 269
Study 16096751 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuver (10 seconds)
Number of subjects: 10
Study 16096751 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuver (20 seconds)
Number of subjects: 10
Study 16096751 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuver (first maneuver)
Number of subjects: 10
Study 16096751 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuver (second maneuver)
Number of subjects: 10
Study 11844417 — intervention group
Group type: EXPERIMENTAL
Intervention: Denture Brite
Number of subjects: 0
Study 11844417 — intervention group
Group type: EXPERIMENTAL
Intervention: Polident
Number of subjects: 0